Cytology and HPV testing is one of the most swiftly developing fields within the field of molecular diagnostics. Cytological screening refers to the examination of the morphology, structure, and function of cells by utilizing a microscope. This type of screening is majorly utilized for the detection of cervical cancers. On the other hand, the human papillomavirus (HPV) test is utilized for the detection of human papillomavirus, a type of virus that can cause the development of cervical cancer and genital warts.
Browse Full Global Cytology and HPV Testing Market Report with TOC :http://www.mrrse.com/cytology-hpv-testing-market
Rising Incidence of HPV Infections to Fuel Cytology and HPV Testing Market
The increasing occurrence of cervical cancer and HPV infections will fuel the growth of the global cytology and HPV testing market. In addition, the increasing number of programs providing awareness on the increasing need for cervical cancer screening will further provide impetus to the growth of this market. Furthermore, emerging nations will provide long-term opportunities to the market for cytology and HPV testing, hence augmenting the growth of the market. However, the absence of adequate primary health infrastructure in some nations and the dearth of awareness on cancer screening may impede the development of this market in forthcoming years.
HPV and Cytology Testing Services Constituted Largest Share in 2015
In terms of product and service, the market is categorized into cytology testing and HPV testing. The segment of cytology testing is further segmented into assay kits, systems, and services. The segment of HPV testing is also segmented into services, assay kits, and systems. Of these, the segment of cytology testing services held the largest share of 78.7% in the cytology testing market in 2015. The increasing number of PAP tests performed globally will contribute to the growth of this segment.
Likewise, the segment of HPV testing services led the HPV testing market and constituted a share of 78.20% in 2015. This is due to the increasing number of women undergoing HPV tests for the diagnosis of cervical cancer globally.
North America Led Market with a Share of 52.5% in 2015
Geographically, the cytology and HPV testing market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, the North America cytology and HPV testing market held the largest share of 52.5% in 2015. The increasing introduction of awareness programs by both private organizations and governments and the growing occurrence of cervical cancer and HPV infections will propel the growth of the market in North America.
Browse the full Press Release of Global Cytology and HPV Testing Market at http://www.mrrse.com/global-cytology-hpv-testing-market
Asia Pacific to Experience Significant Growth from 2016 to 2024
On the other hand, in Europe, the increasing preference for cutting-edge sensitive screening tests and imaging modalities will raise the growth of the market. Asia Pacific is also predicted to experience significant growth in the market from 2016 to 2024. This is owing to the easy availability of adept and low-cost IT labor in this region.
The prime companies dominant in the global cytology and HPV testing market are Cepheid, Inc., Becton, Dickinson and Company, Abbott Laboratories, Inc., Fujirebio Diagnostics, Inc., F. Hoffmann-La Roche AG, Arbor Vita Corporation, QIAGEN N.V., OncoHealth Corporation, and Hologic, Inc., among others.